National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 4609-4610 [2024-01296]

Download as PDF Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices Thayer Agency, Inc., and thereby indirectly retain additional voting shares of Thayer County Bank, both of Hebron, Nebraska. In addition, Rebecca Schure, Omaha, Nebraska, to become a member of the Kenner Family Group, to retain voting shares of Thayer Agency, Inc., and thereby indirectly retain voting shares of Thayer County Bank. Board of Governors of the Federal Reserve System. Ann Misback, Secretary of the Board. [FR Doc. 2024–01348 Filed 1–23–24; 8:45 am] BILLING CODE P OFFICE OF GOVERNMENT ETHICS Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Public Financial Disclosure Extension Request AGENCY: Office of Government Ethics (OGE). Notice and request for comments. ACTION: The Office of Government Ethics (OGE) seeks comment on the development of a new module allowing filers to request an extension of the time available to file a public financial disclosure report within its Integrity electronic filing system. This notice announces that OGE intends to submit this collection to the Office of Management and Budget (OMB) for approval under the Paperwork Reduction Act. DATES: Consideration will be given to all written comments received by March 25, 2024. ADDRESSES: Comments may be submitted to OGE by the following methods: Email: usoge@oge.gov (Include reference to ‘‘Extension Module PRA Comment’’ in the subject line of the message.) Mail: Office of Government Ethics, 250 E Street SW, Suite 750, Washington DC 20024–3249, Attention: Jennifer Matis, Associate Counsel. Instructions: Comments may be posted on OGE’s website, www.oge.gov. Sensitive personal information, such as account numbers or Social Security numbers, should not be included. Comments generally will not be edited to remove any identifying or contact information. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: FOR FURTHER INFORMATION CONTACT: Jennifer Matis at the U.S. Office of Government Ethics; telephone: 202– VerDate Sep<11>2014 17:06 Jan 23, 2024 Jkt 262001 482–9216; TTY: 800–877–8339; Email: jmatis@oge.gov. SUPPLEMENTARY INFORMATION: Title: Electronic Public Financial Disclosure Extension Request. Abstract: The Integrity Public Financial Disclosure Extension Request will be a module within OGE’s Integrity electronic filing application. Certain officers and high-level employees in the executive branch are required to file public financial disclosure reports via the OGE Form 278e and OGE Form 278– T for the purpose of conflict of interest review and public disclosure. The form is also completed by individuals who are nominated by the President for highlevel executive branch positions requiring Senate confirmation and individuals entering into and departing from other public reporting positions in the executive branch. In 2014, OGE sought and received approval to incorporate the OGE Form 278e into its Integrity electronic filing application. Integrity has been in use since January 1, 2015, and most public financial disclosure filers now use Integrity to file the OGE Form 278e and OGE Form 278–T. Although Integrity is primarily used by current executive branch federal employees, it is also used to file termination reports by certain filers who have recently left government service. The proposed module within Integrity will allow filers to easily request an extension of time to file their report. The module can be ‘‘turned on’’ by the filers’ reporting agency, or the agency may choose not to use it. Requests for extensions are currently made by calling or emailing the filer’s agency ethics official and require that the filer provide a reason for requesting an extension. The ethics official can then manually enter the number of days granted into Integrity and those days will be displayed on the cover page of the printed report, which is made public in accordance with 5 U.S.C. 13107. If the extension was granted because the filer is in a combat zone, the reason for the extension is also noted on the report. Once the new feature is deployed and an agency chooses to enable the feature, their filers will request an extension through the Integrity module. The electronic extension request will then be presented within the Integrity application to the appropriate ethics official at the employing agency. If the ethics official grants the request, the required information will automatically appear on the filer’s report as generated by the Integrity application. OGE believes that many agencies will avail themselves of the option to use the PO 00000 Frm 00021 Fmt 4703 Sfmt 4703 4609 new module. For those that do, automating this process will make it easier for both the filer and the agency ethics officials and will reduce the chance that required information will be omitted from the filer’s report. The development of this feature has been ranked a high priority by the Integrity Advisory Council (IAC), which is comprised of a diverse group of agencies that have at least 90% of their financial disclosure filers utilizing the Integrity application. The IAC was established to advise OGE on proposed enhancements, improvements, and support services. OMB Control Number: To Be Determined. Type of Information Collection: New collection. Type of Review Request: Regular. Affected Public: Private citizens who file termination reports from such positions after their government service ends. Estimated Annual Number of Respondents: 511. Estimated Time per Response: 2 minutes. Estimated Total Annual Burden: 17 hours. Request for Comments: Public comment is invited specifically on the need for and practical utility of this information collection, the accuracy of OGE’s burden estimate, the enhancement of quality, utility and clarity of the information collected, and the minimization of burden (including the use of information technology). Comments received in response to this notice will be summarized for, and may be included with, the OGE request for OMB approval under the Paperwork Reduction Act. The comments will also become a matter of public record. Dated: January 18, 2024. Shelley K. Finlayson, Acting Director, U.S. Office of Government Ethics. [FR Doc. 2024–01332 Filed 1–23–24; 8:45 am] BILLING CODE 6345–03–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., E:\FR\FM\24JAN1.SGM 24JAN1 4610 Federal Register / Vol. 89, No. 16 / Wednesday, January 24, 2024 / Notices as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Patient-Oriented Research Study Section. Date: February 29–March 1, 2024. Time: 9:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Fungai Chanetsa, Ph.D., MPH, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 206– B, Bethesda, MD 20817, (301) 402–9394, fungai.chanetsa@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: January 18, 2024. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–01296 Filed 1–23–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Ben Hurley at 240–669–5092, or benjamin.hurley@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 17:06 Jan 23, 2024 Jkt 262001 Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852: tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Hybridoma Cell Lines 2A4 and 5B12 Against Puromycin Description of Technology Protein translation is a central cellular function attracting increasing attention from cell biologists as they integrate gene product specific information into a systems view of cellular function. Scientists at NIAID developed the puromycin-specific antibodies that allow for the specific detection of puromycin-containing nascent polypeptides via standard immunofluorescence or flow cytometry. The resulting ribopuromycylation method (RPM) localizes translation in cells and can be applied to any PMYsensitive eukaryotic or prokaryotic cell to study the dynamics of protein synthesis at the cellular level and investigate translational processes. It can also be used in vitro or in vivo to measure the number of translating ribosomes using flow cytometry. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • Broad application for studying protein translation. Competitive Advantages: • This technology generates antibodies specific for puromycin that can be used to localize translating ribosomes in all cell types. Development Stage: • Research Materials Inventors: Jonathan Yewdell, MD, Ph.D., Alexandre David, Ph.D., both of NIAID. Publications: David A. Dolan BP, Hickman HD, Knowlton JJ, Clavarino G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J Cell Biol. 2012 Apr 2;197(1):45–57. doi: 10.1083/ jcb.201112145. PMID: 22472439; PMCID: PMC3317795. Also: PMID 29552591, 27385780, 25311127, 23229864. Intellectual Property: HHS Reference No. E–003–2021. Licensing Contact: To license this technology, please contact Ben Hurley PO 00000 Frm 00022 Fmt 4703 Sfmt 4703 at 240–669–5092, or benjamin.hurley@ nih.gov, and reference E–003–2021. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Ben Hurley at 240–669–5092, or benjamin.hurley@nih.gov. Dated: January 19, 2024. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2024–01364 Filed 1–23–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics in Biobehavioral Processes. Date: February 15, 2024. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jeanne M. McCaffery, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–594–3854, jeanne.mccaffery@ nih.gov. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Chemical Biology and Probes Study Section. Date: February 15–16, 2024. Time: 10:00 a.m. to 8:30 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\24JAN1.SGM 24JAN1

Agencies

[Federal Register Volume 89, Number 16 (Wednesday, January 24, 2024)]
[Notices]
[Pages 4609-4610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01296]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C.,

[[Page 4610]]

as amended. The grant applications and the discussions could disclose 
confidential trade secrets or commercial property such as patentable 
material, and personal information concerning individuals associated 
with the grant applications, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: Heart, Lung, and Blood Initial Review Group; 
NHLBI Mentored Patient-Oriented Research Study Section.
    Date: February 29-March 1, 2024.
    Time: 9:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge I, 6705 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Fungai Chanetsa, Ph.D., MPH, Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, National Institutes of Health, 6705 Rockledge 
Drive, Room 206-B, Bethesda, MD 20817, (301) 402-9394, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: January 18, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01296 Filed 1-23-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.